Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) and sodium/glucose cotransporter 2 inhibitors (SGLT2is) have been introduced for the treatment of type 2 diabetes mellitus (T2DM). This evidence concerns the gene GLP1R and type 2 diabetes mellitus.